The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate in the study; be able to complete the study as per protocol requirements;
Aged ≥ 18 years AND ≤ 75 years at the time of signing the ICF, male or female;
Histologically or cytologically confirmed advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Locally advanced or metastatic Gastric or Gastroesophageal Junction Adenocarcinoma that has failed or progressed after at least one standard systemic treatment in the past, or has experienced intolerable toxicity (CTCAE≥ grade 3), or has contraindications to standard treatment and is not suitable for radical treatment.
Have previously received any drug treatment targeting topoisomerase I, including chemotherapy and ADC.
Radical radiation therapy within 3 months prior to the first dose;
History of any second malignancy within 2 years prior to randomization, except for early-stage malignancies (carcinoma in situ or stage I tumors) that have received radical treatment, such as non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer, ductal carcinoma in situ of the breast, and papillary thyroid carcinoma;
History of adverse events leading to permanent discontinuation of immunotherapy, or occurrence of ≥ Grade 2 immune-related pneumonitis or myocarditis during prior immunotherapy;